抗 HBc IgG 水平：核苷（酸）类似物诱导的 HBeAg 血清清除的慢

StephenW

抗 HBc IgG 水平：核苷（酸）类似物诱导的 HBeAg 血清清除的慢性乙型肝炎患者 HBsAg 血清清除的预测因子

    Saein Kim, Sunghwan Yoo, Jung Il Lee, Sora Kim, Hye Young Chang, Dokyun Kim, Seok Hoon Jeong, Kwan Sik Lee & Hyun Woong Lee

消化疾病与科学第 67 卷，第 321–328 页（2022 年）引用这篇文章

    821 次访问

    指标详情

抽象的
背景/目标

我们研究了抗 HBc IgG 间接比率在预测核苷（酸）类似物 (NA) 诱导的 HBeAg 血清清除患者中 HBsAg 血清清除方面的效率。
方法

我们在一家三级医院进行了一项回顾性研究，纳入了 366 名慢性乙型肝炎患者（2007 年 3 月至 2016 年 12 月）。这些患者 HBsAg 血清学阳性，并且经历了 NA 诱导的 HBeAg 血清学清除。使用 Architect Anti-HBc 测定法（Abbott Laboratories，IL，USA）作为抗病毒治疗前的定性方法，通过化学发光微粒免疫测定法测量抗 HBc IgG 水平的光吸收的间接比率。我们根据抗 HBc IgG 水平计算了 HBsAg 血清清除的累积发生率。
结果

经过 10 年的随访，48 名患者出现 HBsAg 血清学清除（13.1%）。 179 例抗 HBc IgG 光吸收间接比率 < 11 RLU（相对光单位）的患者中有 33 例显示 HBsAg 血清学清除（18.4%）； 187 例抗 HBc IgG ≥ 11 RLU 光吸收间接比率的患者中有 15 例显示 HBsAg 血清学耐受（8.0%）（p = 0.003）。在多变量分析中，HBeAg 血清学清除时的年龄和 ALT 是 HBsAg 血清学清除的预测因素。特别是，与基线时抗 HBc IgG 水平较高的患者相比，基线抗 HBc IgG 水平 < 11 RLU 的患者 HBsAg 血清学清除的相对风险为 2.213（95% CI，1.220–4.014）（p = 0.009)。
结论

使用间接方法检测抗 HBc IgG 水平，基线抗 HBc IgG 水平 (< 11RLU)、年龄 (≥ 50 岁) 和 ALT (≥ 40 IU/L) 可能与 NA 诱导患者的 HBsAg 血清学清除有关HBeAg 血清学清除。

StephenW

Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance

    Saein Kim, Sunghwan Yoo, Jung Il Lee, Sora Kim, Hye Young Chang, Dokyun Kim, Seok Hoon Jeong, Kwan Sik Lee & Hyun Woong Lee

Digestive Diseases and Sciences volume 67, pages 321–328 (2022)Cite this article

    821 Accesses

    Metrics details

Abstract
Background/Aims

We investigated the efficiency of the indirect ratio of anti-HBc IgG at predicting HBsAg seroclearance in patients with nucleos(t)ide analogue (NA)-induced HBeAg seroclearance.
Methods

We performed a retrospective study that included 366 chronic hepatitis B patients (March 2007 to December 2016) at a single tertiary hospital. These patients were HBsAg seropositive, and experienced NA-induced HBeAg seroclearance. The indirect ratio of light absorbance of anti-HBc IgG levels were measured with chemiluminescent microparticle immunoassay using the Architect Anti-HBc assay (Abbott Laboratories, IL, USA) as a qualitative method prior to antiviral therapy. We calculated the cumulative incidences of HBsAg seroclearance based on the anti-HBc IgG levels.
Results

After a 10-year follow-up, 48 patients experienced HBsAg seroclearance (13.1%). Thirty-three of 179 patients who had an indirect ratio of light absorbance of anti-HBc IgG < 11 RLU (relative light unit) showed HBsAg seroclearance (18.4%); 15 of 187 patients who had an indirect ratio of light absorbance of anti-HBc IgG ≥ 11 RLU showed HBsAg seroclerance (8.0%) (p = 0.003). In multivariate analysis, age, and ALT at the time of HBeAg seroclearance were predictors of HBsAg seroclearance. Especially, the relative risk of HBsAg seroclearance in patients with baseline anti-HBc IgG levels < 11 RLU was 2.213 (95% CI, 1.220–4.014), compared to that in patients with higher levels of anti-HBc IgG at baseline (p = 0.009).
Conclusion

Using an indirect method for anti-HBc IgG levels, baseline anti-HBc IgG levels (< 11RLU), age (≥ 50 years), and ALT (≥ 40 IU/L) might be associated with HBsAg seroclearance in patients with NA-induced HBeAg seroclearance.

StephenW

https://link.springer.com/articl ... c_springer_20220108